When patients start tirzepatide (Zepbound) for obesity, the number on the scale is usually the most visible outcome. But obesity treatment is ultimately about health, not simply weight. A newly published analysis from the SURMOUNT clinical-trial program asks a useful question: how often do patients improve several important cardiometabolic measures at the same time? What
1. Orforglipron after Wegovy or Zepbound. ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion. https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/ 2. CagriSema vs. Zepbound. CagriSema delivered 23% average weight loss in its head-to-head trial —
Foundayo (orforglipron) brings GLP-1 obesity treatment into a once-daily pill with no food or water restrictions — changing how some patients approach initiation and maintenance therapy.
CagriSema produced 20%+ average weight loss versus placebo — but in the REDEFINE 4 head-to-head it did not prove non-inferior to tirzepatide. Here is what both results mean.
ATTAIN-MAINTAIN found that patients switched from tirzepatide or semaglutide to oral orforglipron preserved substantially more prior weight loss than those switched to placebo.
This week’s News Flash highlights five clinically useful publications appearing in the August literature. The emphasis is on treatment persistence, body composition, oral obesity medications, and practical decisions about treatment goals. 1. Why Do Patients Stop GLP-1 Medications? A New National Survey Adds Real-World Detail Evidence status: Peer-reviewed national survey A newly published U.S. survey
